A significant flaw has been identified in the Trump administration's most-favored nation drug pricing plans, according to a senior health official's comments.
This development raises questions about the viability of the proposed reforms and their potential impact on healthcare infrastructure.
Additionally, insights into a new deal involving Gilead are emerging, which could have implications for drug availability and pricing strategies.